-

Vetoquinol: Availability of the 2020 Universal Registration Document

LURE, France--(BUSINESS WIRE)--Regulatory News:

Vetoquinol (Paris:VETO) informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

The 2020 Universal Registration Document is available to the public, free of charge under the conditions provided by applicable regulations and may be consulted on the “Investors” page of the Group’s website (www.vetoquinol.com), in the “Regulated Information” section. It is also available on the AMF’s website (www.amf-france.org).

The 20202 Universal Registration Document includes:

  • the 2020 Annual Financial Report;
  • the Management Report;
  • the Board of Directors Report on Corporate Governance;
  • the Extra-Financial Performance Declaration;
  • the information related to the fees paid to the Statutory Auditors;
  • the share buyback program description; and
  • the agenda and draft resolutions of the Shareholder’s Meeting of May 27th, 2021.

Next update: Shareholders’ meeting, May 27th, 2021

ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has been pursuing a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At December 31st 2020, Vetoquinol employs 2,409 people.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

Contacts

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor & Media Relations
Emmanuel Dovergne
Tel.: +33 (0) 1 56 43 44 63
emmanuel.dovergne@keima.fr

Vetoquinol

BOURSE:VETO

Release Versions

Contacts

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor & Media Relations
Emmanuel Dovergne
Tel.: +33 (0) 1 56 43 44 63
emmanuel.dovergne@keima.fr

More News From Vetoquinol

Vetoquinol: 2025 Annual Results

LURE, France--(BUSINESS WIRE)--Regulatory News: Commenting on the 2025 fiscal year, Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), stated, “In an extremely volatile environment, Vetoquinol has once again this year demonstrated the resilience of its business model, driven by a long-term strategic vision which, combined with our proactive management of expenses, enables us to deliver a healthy level of profitability. We will actively pursue this strategy, relying in particular on...

Vetoquinol: 2025 Annual Sales

LURE, France--(BUSINESS WIRE)--Regulatory News: In an economy marked by unusual exchange rate volatility, Vetoquinol (Paris:VETO) achieved two important objectives: growth in Essential products and internalization of the manufacturing of the parasiticide range. Vetoquinol's sales for FY 2025 came to €525.7 million, up 0.2% at constant exchange rates and down 2.5% on a reported basis. Over the financial year, the company recorded historically high negative currency impacts of €14.8 million in al...

Vetoquinol: Sales at End September 2025

LURE, France--(BUSINESS WIRE)--Regulatory News: At the end of September 2025, Vetoquinol's (Paris:VETO) sales amounted to €384.2 million, down 3.5% on a reported basis and down 1.3% at constant exchange rates. Over this period, the Group recorded net negative currency impacts of €8.9 million in the Americas and Asia-Pacific/Rest of the World regions and an impact of - €7.7 million from the simplification of complementary ranges, mainly in Europe. Net of these two items, sales for the first nine...
Back to Newsroom